Rammohan Ashwin, Sathyanesan Jeswanth, Rajendran Kamalakannan, Pitchaimuthu Anbalagan, Perumal Senthil K, Balaraman Kesavan, Ramasamy Ravi, Palaniappan Ravichandran, Govindan Manoharan
The Institute of Surgical Gastroenterology & Liver Transplantation, Centre for GI Bleed, Division of Hepato-biliary Pancreatic Diseases, Govt, Stanley Medical College Hospital & Hospital Chennai, India.
HPB (Oxford). 2015 Jun;17(6):508-13. doi: 10.1111/hpb.12383. Epub 2015 Jan 9.
Obstructive jaundice as a result of bile duct tumour thrombus (BDTT) is an unusual clinical entity and an uncommon presenting feature of hepatocellular carcinoma (HCC). This study evaluates the outcome of hepatectomy for HCC with obstructive jaundice as a result of BDTT in non-cirrhotic livers.
Between 1997 and 2012, out of 426 patients with HCC in non-cirrhotic livers, 39 patients with BDTT (Group I n = 39), who underwent a hepatectomy, were analysed and compared with the non-BDTT group (Group II n = 387).
The demographic profile and biochemical parameters between Group I and Group II were compared; apart from the presence of jaundice at presentation and an elevated serum bilirubin, there were no significant differences. Post-operative morbidity and mortality were 11 (28.2%) and 2 (5.1%), respectively, in Group I. There were no differences between the groups with regards to the operative variables and short-term outcomes. The 1-, 3- and 5-year survival rates in Group I were 82%, 48% and 10%, respectively, with a median survival of 28.6 months and were significantly poorer than Group II (90%, 55% and 38%, respectively, with a median survival of 39.2 months).
The mere presence of BDTT in HCC does not indicate an advanced or inoperable lesion. When technically feasible, a formal hepatic resection is the preferred first-line treatment option in these patients.
胆管肿瘤血栓(BDTT)导致的梗阻性黄疸是一种不常见的临床病症,也是肝细胞癌(HCC)不常见的表现特征。本研究评估了非肝硬化肝脏中因BDTT导致梗阻性黄疸的HCC患者肝切除术后的结局。
1997年至2012年间,在426例非肝硬化肝脏的HCC患者中,对39例接受肝切除术的BDTT患者(I组,n = 39)进行分析,并与非BDTT组(II组,n = 387)进行比较。
比较了I组和II组的人口统计学特征和生化参数;除了就诊时存在黄疸和血清胆红素升高外,没有显著差异。I组术后发病率和死亡率分别为11例(28.2%)和2例(5.1%)。两组在手术变量和短期结局方面没有差异。I组的1年、3年和5年生存率分别为82%、48%和10%,中位生存期为28.6个月,明显低于II组(分别为90%、55%和38%,中位生存期为39.2个月)。
HCC中单纯存在BDTT并不表明病变已进展或无法手术。在技术可行时,正规肝切除术是这些患者首选的一线治疗方案。